Ovarian Cancer Relapse Causing Fluid Around the Heart
This ovarian cancer diagnosis at a glance
- Biomarkers
- PAX8 positive; CK7 positive; WT1 positive; p53 positive; ER positive; PR negative; isolated PMS2 loss; MSH2 retained; MSH6 retained; MLH1 retained; two BRCA1 variants of uncertain significance
- Sex
- Female
- Spread to
- omentum|pericardium
- Treatment
- surgery, chemotherapy and targeted therapy
- Outcome
- Care Ongoing
Treatment course, step by step
- She underwent tumor-reduction surgery and completed 6 cycles of paclitaxel and carboplatin.
- Seven years later, fluid around the heart was surgically drained.
- She then received another paclitaxel and carboplatin course and began olaparib maintenance.
What happened, in summary
A 51-year-old woman sought care in 2010 for 2 months of lower abdominal pain, abdominal heaviness, and loss of appetite. Imaging showed masses in both ovaries with ascites, and her CA-125 was 86 IU/mL. She underwent hysterectomy, removal of both ovaries and fallopian tubes, omentectomy, and tumor-reduction surgery. Pathology confirmed high-grade serous ovarian carcinoma involving both ovaries, nearby tissue, the right fallopian tube, and the omentum. The cancer was Stage IIIC, and some disease remained near the rectosigmoid and ileocecal bowel regions.
She completed 6 cycles of paclitaxel and carboplatin every 3 weeks. Imaging and clinical review found no disease immediately after chemotherapy, and CA-125 fell to 7.9 IU/mL. She continued regular follow-up.
Seven years later, she developed 20 days of breathing difficulty, chest pain, fatigue, and leg swelling. A hemorrhagic pericardial effusion was compressing her heart. Doctors drained 200 mL of fluid, then created a surgical pericardial window and removed another 300 mL. Cytology and immunostaining confirmed that the cancer around the heart came from the ovarian primary.
Four weeks later, she restarted paclitaxel and carboplatin. Testing showed isolated PMS2 loss and 2 BRCA1 variants of uncertain significance, which were not established as disease-causing mutations. She completed chemotherapy and was alive on olaparib maintenance at the latest follow-up.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Metastatic Ovarian Cancer 11 stories
- Carboplatin for Ovarian Cancer 58 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer